drugset

drugset / Trial / NCT07226661

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

NCT07226661 ↗

Phase 2 Recruiting 230 enrolled Supernus Pharmaceuticals, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder

Timeline

Start: 2026-01-19
Primary completion: 2026-12-31
Completion: 2027-01-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SPN-821	Unknown	2400 mg	Oral

Indications